BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caraceni P, Domenicali M, Bernardi M. The endocannabinoid system and liver diseases. J Neuroendocrinol 2008;20 Suppl 1:47-52. [PMID: 18426499 DOI: 10.1111/j.1365-2826.2008.01679.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
Number Citing Articles
1 Caraceni P, Domenicali M, Giannone F, Bernardi M. The role of the endocannabinoid system in liver diseases. Best Pract Res Clin Endocrinol Metab. 2009;23:65-77. [PMID: 19285261 DOI: 10.1016/j.beem.2008.10.009] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
2 Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009;3:294-304. [PMID: 19669380 DOI: 10.1007/s12072-008-9109-7] [Cited by in Crossref: 114] [Cited by in F6Publishing: 98] [Article Influence: 8.8] [Reference Citation Analysis]
3 Chitturi S. Treatment options for nonalcoholic Fatty liver disease. Therap Adv Gastroenterol 2008;1:173-89. [PMID: 21180527 DOI: 10.1177/1756283X08096951] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
4 de Souza SLB, Mota GAF, Gregolin CS, do Nascimento M, Luvizotto RAM, Bazan SGZ, Sugizaki MM, Barbisan LF, Cicogna AC, do Nascimento AF. Exercise Training Attenuates Cirrhotic Cardiomyopathy. J of Cardiovasc Trans Res 2021;14:674-84. [DOI: 10.1007/s12265-020-09997-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Lin H, Yang Y, Tsai T, Huang C, Huang Y, Lee F, Liu T, Lee S. The relationship between endotoxemia and hepatic endocannabinoids in cirrhotic rats with portal hypertension. Journal of Hepatology 2011;54:1145-53. [DOI: 10.1016/j.jhep.2010.09.026] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
6 Patsenker E, Stoll M, Millonig G, Agaimy A, Wissniowski T, Schneider V, Mueller S, Brenneisen R, Seitz HK, Ocker M. Cannabinoid receptor type I modulates alcohol-induced liver fibrosis. Mol Med. 2011;17:1285-1294. [PMID: 21863215 DOI: 10.2119/molmed.2011.00149] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 4.3] [Reference Citation Analysis]
7 Argemi J, Bataller R. Hepatocyte-stellate cell synapse in alcohol-induced steatosis: another role for endocannabinoids. Nat Rev Gastroenterol Hepatol 2020;17:5-6. [PMID: 31686014 DOI: 10.1038/s41575-019-0233-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Floreani A, Lazzari R, Macchi V, Porzionato A, Variola A, Colavito D, Leon A, Guido M, Baldo V, De Caro R, Bergasa NV. Hepatic expression of endocannabinoid receptors and their novel polymorphisms in primary biliary cirrhosis. J Gastroenterol 2010;45:68-76. [PMID: 19730968 DOI: 10.1007/s00535-009-0122-y] [Cited by in Crossref: 23] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
9 Lanthier N, Horsmans Y, Leclercq IA. The metabolic syndrome: how it may influence hepatic stellate cell activation and hepatic fibrosis. Curr Opin Clin Nutr Metab Care. 2009;12:404-411. [PMID: 19474722 DOI: 10.1097/mco.0b013e32832c7819] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 2.7] [Reference Citation Analysis]
10 Ligresti A, Petrosino S, Di Marzo V. From endocannabinoid profiling to ‘endocannabinoid therapeutics’. Current Opinion in Chemical Biology 2009;13:321-31. [DOI: 10.1016/j.cbpa.2009.04.615] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 4.9] [Reference Citation Analysis]
11 Carvalho MVH, Kroll PC, Kroll RTM, Carvalho VN. Cirrhotic cardiomyopathy: the liver affects the heart. Braz J Med Biol Res 2019;52:e7809. [PMID: 30785477 DOI: 10.1590/1414-431X20187809] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
12 Zhang Z, Guo Y, Zhang S, Zhang Y, Wang Y, Ni W, Kong D, Chen W, Zheng S. Curcumin modulates cannabinoid receptors in liver fibrosis in vivo and inhibits extracellular matrix expression in hepatic stellate cells by suppressing cannabinoid receptor type-1 in vitro. Eur J Pharmacol 2013;721:133-40. [PMID: 24076327 DOI: 10.1016/j.ejphar.2013.09.042] [Cited by in Crossref: 38] [Cited by in F6Publishing: 36] [Article Influence: 4.8] [Reference Citation Analysis]
13 Bátkai S, Pacher P. Endocannabinoids and cardiac contractile function: pathophysiological implications. Pharmacol Res 2009;60:99-106. [PMID: 19569260 DOI: 10.1016/j.phrs.2009.04.003] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.0] [Reference Citation Analysis]
14 Ranney DN, Acker WB, Al-holou SN, Ehrlichman L, Lee DS, Lewin SA, Nguyen C, Peterson SF, Sell K, Kubus J, Reid D, Englesbe MJ. Marijuana Use in Potential Liver Transplant Candidates. American Journal of Transplantation 2009;9:280-5. [DOI: 10.1111/j.1600-6143.2008.02468.x] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 4.3] [Reference Citation Analysis]